Download PDF
CC BY 4.0 · TH Open 2022; 06(03): e168-e176
DOI: 10.1055/s-0042-1750378
Original Article

Venous Thromboembolism in Surgically Treated Esophageal Cancer Patients: A Provincial Population-Based Study

Gileh-Gol Akhtar-Danesh
1   Department of Surgery, McMaster University, Hamilton, Ontario, Canada
,
Noori Akhtar-Danesh
2   School of Nursing, McMaster University, Hamilton, Ontario, Canada
3   Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
,
Yaron Shargall
1   Department of Surgery, McMaster University, Hamilton, Ontario, Canada
4   Division of Thoracic Surgery, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints


Abstract

Objective Venous thromboembolism (VTE) is a major cause of morbidity and mortality in surgical patients. Surgery for esophageal cancer carries a high risk of VTE. This study identifies the risk factors and associated mortality of thrombotic complications among patients undergoing esophageal cancer surgery.

Methods All patients in the province of Ontario undergoing esophageal cancer surgery from 2007 to 2017 were identified. Logistic regression identified VTE risk factors at 90 days and 1 year postoperatively. A flexible parametric survival analysis compared mortality and survival up to 5 years after surgery for patients with and without a postoperative VTE.

Results Overall 9,876 patients with esophageal cancer were identified; 2,536 (25.7%) underwent surgery. VTE incidence at 90 days and 1 year postoperatively were 4.1 and 6.3%, respectively. Patient factors including age, sex, performance status, and comorbidities were not associated with VTE risk. VTE risk peaked at 1 month after surgery, with a subsequent decline, plateauing after 6 months. Adenocarcinoma was strongly associated with VTE risk compared with squamous cell carcinoma (SCC) (odds ratio [OR] 2.53, 95% confidence interval [CI] 1.38–4.63, p = 0.003). VTE risk decreased with adjuvant chemotherapy (OR = 0.58, 95% CI 0.36–0.94, p = 0.028). Postoperative VTE was associated with decreased survival at 1 and 5 years (hazard ratio = 1.57, 95% CI 1.23–2.00, p < 0.001).

Conclusion Esophageal cancer patients with postoperative VTE have worse long-term survival compared with those without thrombotic complications. Adenocarcinoma carries a higher VTE risk compared with SCC. Strategies to reduce VTE risk should be considered to reduce the negative impacts on survival conferred by thrombotic events.

Keywords

esophageal cancer - extended prophylaxis - venous thromboembolism - long-term survival

Ethics Approval

The Hamilton Integrated Research Ethics Board (HiREB) provided approval for this study in August 2019, approval number 7771-C.




Publication History

Received: 11 January 2022

Accepted: 29 April 2022

Article published online:
11 July 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Di Nisio M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. Lancet 2016; 388 (10063): 3060-3073
    CrossrefPubMedSearch in Google Scholar
  • 2 Goldhaber SZ. Deep Vein Thrombosis: Advancing Awareness to Protect Patient Lives. American Public Health Association;; 2003 Accessed August 29, 2020 at: http://cl-natf-002.masstechnology.com/docs/pdf/APHAWhitePaperonDeep-VeinThrombosis.pdf
    PubMedSearch in Google Scholar
  • 3 Falanga A. The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment. Cancer Invest 2009; 27 (01) 105-115
    CrossrefPubMedSearch in Google Scholar
  • 4 Key NS, Khorana AA, Kuderer NM. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2020; 38 (05) 496-520
    CrossrefPubMedSearch in Google Scholar
  • 5 Gould MK, Garcia DA, Wren SM. et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2, Suppl): e227S-e277S
    CrossrefPubMedSearch in Google Scholar
  • 6 Falck-Ytter Y, Francis CW, Johanson NA. et al. Prevention of VTE in orthopedic surgery patients. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2, Suppl): e278S-e325S
    CrossrefPubMedSearch in Google Scholar
  • 7 Rasmussen MS, Jørgensen LN, Wille-Jørgensen P. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev 2009; (01) CD004318
    PubMedSearch in Google Scholar
  • 8 Batchelor TJP, Rasburn NJ, Abdelnour-Berchtold E. et al. Guidelines for enhanced recovery after lung surgery: recommendations of the Enhanced Recovery After Surgery (ERAS®) Society and the European Society of Thoracic Surgeons (ESTS). Eur J Cardiothorac Surg 2019; 55 (01) 91-115
    CrossrefPubMedSearch in Google Scholar
  • 9 Shargall Y, Litle VR. European perspectives in thoracic surgery, the ESTS venous thromboembolism (VTE) working group. J Thorac Dis 2018; 10 (Suppl. 08) S963-S968
    CrossrefPubMedSearch in Google Scholar
  • 10 Shinagare AB, Guo M, Hatabu H. et al. Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center. Cancer 2011; 117 (16) 3860-3866
    CrossrefPubMedSearch in Google Scholar
  • 11 Rollins KE, Peters CJ, Safranek PM, Ford H, Baglin TP, Hardwick RH. Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery. Eur J Surg Oncol 2011; 37 (12) 1072-1077
    CrossrefPubMedSearch in Google Scholar
  • 12 Mantziari S, Gronnier C, Pasquer A. et al; FREGAT Working Group–FRENCH–AFC. Incidence and risk factors related to symptomatic venous thromboembolic events after esophagectomy for cancer. Ann Thorac Surg 2016; 102 (03) 979-984
    CrossrefPubMedSearch in Google Scholar
  • 13 Agzarian J, Litle V, Linkins L-A. et al. International Delphi survey of the ESTS/AATS/ISTH task force on venous thromboembolism prophylaxis in thoracic surgery: the role of extended post-discharge prophylaxis. Eur J Cardiothorac Surg 2020; 57 (05) 854-859
    CrossrefPubMedSearch in Google Scholar
  • 14 Agzarian J, Linkins LA, Schneider L. et al. Practice patterns in venous thromboembolism (VTE) prophylaxis in thoracic surgery: a comprehensive Canadian Delphi survey. J Thorac Dis 2017; 9 (01) 80-87
    CrossrefPubMedSearch in Google Scholar
  • 15 Merkow RP, Bilimoria KY, McCarter MD. et al. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg 2011; 254 (01) 131-137
    CrossrefPubMedSearch in Google Scholar
  • 16 ClinicalTrials.gov. Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery. National Library of Medicine;; 2018
    Search in Google Scholar
  • 17 Statistics Canada. Population estimates, quarterly. Published 2020. Accessed December 28, 2020 at: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000901
    PubMed
  • 18 Booth CM, Li G, Zhang-Salomons J, Mackillop WJ. The impact of socioeconomic status on stage of cancer at diagnosis and survival: a population-based study in Ontario, Canada. Cancer 2010; 116 (17) 4160-4167
    CrossrefPubMedSearch in Google Scholar
  • 19 Juurlink D, Preyra C, Croxford R. et al. Canadian Institute for Health Information Discharge Abstract Database: A Validation Study. Toronto;: 2006
    Search in Google Scholar
  • 20 ICES. About ICES Research. Published 2021. Accessed May 1, 2021 at: https://www.ices.on.ca/Research/About-ICES-Research
    PubMed
  • 21 Revenig LM, Canter DJ, Taylor MD. et al. Too frail for surgery? Initial results of a large multidisciplinary prospective study examining preoperative variables predictive of poor surgical outcomes. J Am Coll Surg 2013; 217 (04) 665-670 .e1
    CrossrefPubMedSearch in Google Scholar
  • 22 Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 2002; 21 (15) 2175-2197
    CrossrefPubMedSearch in Google Scholar
  • 23 Lambert PC, Royston P. Further Development of Flexible Parametric Models for Survival Analysis. Vol. 9;. 2009 Accessed September 7, 2020 at: https://journals.sagepub.com/doi/pdf/10.1177/1536867x0900900206
    PubMedSearch in Google Scholar
  • 24 Rutherford MJ, Dickman PW, Lambert PC. Comparison of methods for calculating relative survival in population-based studies. Cancer Epidemiol 2012; 36 (01) 16-21
    CrossrefPubMedSearch in Google Scholar
  • 25 Agnelli G, Bolis G, Capussotti L. et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006; 243 (01) 89-95
    CrossrefPubMedSearch in Google Scholar
  • 26 Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel) 2018; 10 (10) E380
    CrossrefPubMedSearch in Google Scholar
  • 27 Dickmann B, Ahlbrecht J, Ay C. et al. Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica 2013; 98 (08) 1309-1314
    CrossrefPubMedSearch in Google Scholar
  • 28 Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006; 118 (05) 555-568
    CrossrefPubMedSearch in Google Scholar
  • 29 Cronin-Fenton DP, Søndergaard F, Pedersen LA. et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer 2010; 103 (07) 947-953
    CrossrefPubMedSearch in Google Scholar
  • 30 Marshall-Webb M, Bright T, Price T, Thompson SK, Watson DI. Venous thromboembolism in patients with esophageal or gastric cancer undergoing neoadjuvant chemotherapy. Dis Esophagus 2017; 30 (02) 1-7
    PubMedSearch in Google Scholar
  • 31 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110 (10) 2339-2346
    CrossrefPubMedSearch in Google Scholar
  • 32 Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343 (25) 1846-1850
    CrossrefPubMedSearch in Google Scholar
  • 33 Auer RAC, Scheer AS, McSparron JI. et al. Postoperative venous thromboembolism predicts survival in cancer patients. Ann Surg 2012; 255 (05) 963-970
    CrossrefPubMedSearch in Google Scholar
  • 34 Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348 (9022): 224-228
    CrossrefPubMedSearch in Google Scholar
  • 35 Bergqvist D, Agnelli G, Cohen AT. et al; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346 (13) 975-980
    CrossrefPubMedSearch in Google Scholar